BridgeMD
Tests treatment safety and results for H Pylori Gastritis
Official title Efficacy of Carminal in Helicobacter Pylori Gastritis
ClinicalTrials.gov ID: NCT07179237
What this study is testing
- What it's testing
- Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 12 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients aged 18 years or older
- Patients with clinical symptoms of dyspepsia
- Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology
- Patients who give written informed consent to participate in the study
You likely can't join if
- Patients with peptic ulcer disease
- Patients with previous gastric surgery
- Patients with current malignancy or the history of any previous malignancies
- Patients taking another investigational product, or have taken any investigational product in the last year
- Patients with known hypersensitivity to any ingredients found in the investigational product.
- Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac...
See the full eligibility criteria
- Patients aged 18 years or older
- Patients with clinical symptoms of dyspepsia
- Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology
- Patients who give written informed consent to participate in the study
- Patients with peptic ulcer disease
- Patients with previous gastric surgery
- Patients with current malignancy or the history of any previous malignancies
- Patients taking another investigational product, or have taken any investigational product in the last year
- Patients with known hypersensitivity to any ingredients found in the investigational product.
- Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver disease, and psychiatric illnesses that may limit adherence...
- Planned pregnancy for the duration of trial, pregnancy, breast feeding, or postpartum period.
- Patients with human immunodeficiency virus (HIV).
The study team makes the final eligibility decision.
Where it's taking place
- Belgrade, Central Serbia, Serbia
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Belgrade, Central Serbia, Serbia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.